BMEA Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Biomea Fusion, Inc.'s net margin of 16.99%. Biomea Fusion, Inc.'s return on equity of -239.98% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

Biomea Fusion, Inc. has a consensus price target of $7.00, signalling upside risk potential of 410.95%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 37.27%. Given that Biomea Fusion, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Biomea Fusion, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

Biomea Fusion, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.

Biomea Fusion, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomea Fusion, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Biomea Fusion, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Biomea Fusion, Inc.'s net income of -$16.4M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Biomea Fusion, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 147.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomea Fusion, Inc. is -- versus 11.97x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

BioMarin Pharmaceutical, Inc. has a net margin of -- compared to Biomea Fusion, Inc.'s net margin of -5.33%. Biomea Fusion, Inc.'s return on equity of -239.98% beat BioMarin Pharmaceutical, Inc.'s return on equity of 5.89%.

Biomea Fusion, Inc. has a consensus price target of $7.00, signalling upside risk potential of 410.95%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.17 which suggests that it could grow by 42.84%. Given that Biomea Fusion, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Biomea Fusion, Inc. is more attractive than BioMarin Pharmaceutical, Inc..

Biomea Fusion, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.

Biomea Fusion, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomea Fusion, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.

Biomea Fusion, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $874.6M. Biomea Fusion, Inc.'s net income of -$16.4M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$46.6M. Notably, Biomea Fusion, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 34.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomea Fusion, Inc. is -- versus 3.73x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Integra LifeSciences Holdings Corp. has a net margin of -- compared to Biomea Fusion, Inc.'s net margin of -0.39%. Biomea Fusion, Inc.'s return on equity of -239.98% beat Integra LifeSciences Holdings Corp.'s return on equity of -41.72%.

Biomea Fusion, Inc. has a consensus price target of $7.00, signalling upside risk potential of 410.95%. On the other hand Integra LifeSciences Holdings Corp. has an analysts' consensus of $15.13 which suggests that it could grow by 32.91%. Given that Biomea Fusion, Inc. has higher upside potential than Integra LifeSciences Holdings Corp., analysts believe Biomea Fusion, Inc. is more attractive than Integra LifeSciences Holdings Corp..

Biomea Fusion, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Integra LifeSciences Holdings Corp. has a beta of 1.036, suggesting its more volatile than the S&P 500 by 3.641%.

Biomea Fusion, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra LifeSciences Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomea Fusion, Inc. pays -- of its earnings as a dividend. Integra LifeSciences Holdings Corp. pays out -- of its earnings as a dividend.

Biomea Fusion, Inc. quarterly revenues are --, which are smaller than Integra LifeSciences Holdings Corp. quarterly revenues of $434.9M. Biomea Fusion, Inc.'s net income of -$16.4M is lower than Integra LifeSciences Holdings Corp.'s net income of -$1.7M. Notably, Biomea Fusion, Inc.'s price-to-earnings ratio is -- while Integra LifeSciences Holdings Corp.'s PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomea Fusion, Inc. is -- versus 0.53x for Integra LifeSciences Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Savara, Inc. has a net margin of -- compared to Biomea Fusion, Inc.'s net margin of --. Biomea Fusion, Inc.'s return on equity of -239.98% beat Savara, Inc.'s return on equity of -78.83%.

Biomea Fusion, Inc. has a consensus price target of $7.00, signalling upside risk potential of 410.95%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 81.11%. Given that Biomea Fusion, Inc. has higher upside potential than Savara, Inc., analysts believe Biomea Fusion, Inc. is more attractive than Savara, Inc..

Biomea Fusion, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.

Biomea Fusion, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomea Fusion, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.

Biomea Fusion, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Biomea Fusion, Inc.'s net income of -$16.4M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Biomea Fusion, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomea Fusion, Inc. is -- versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.